Coronapod: The divisive hydroxychloroquine study that’s triggering mass confusion

Nature

Noah Baker and Richard Van Noorden discuss the latest COVID-19 news.

In this episode:

00:59 Chloroquine on rocky ground

President Trump’s preferred coronavirus treatment is the focus of a new study suggesting it could cause more harm than good, but not everybody agrees. We discuss the fallout as trials around the world are paused and countries diverge over policy advice.

News: India expands use of controversial coronavirus drug amid safety concerns

News: Safety fears over hyped drug hydroxychloroquine spark global confusion

12:12 Are we rushing science?

Coronavirus papers are being published extremely quickly, while normally healthy scientific debate is being blown up in the world’s press. Is there a balancing act between timely research and accurate messaging?

18:49 One good thing

Our hosts pick out things that have made them smile in the last week, including hedgerow brews and a trip into the past using AI.

Recipe: Elderflower ‘Champagne’

Video: Denis Shiryaev restores historic footage with AI

22:30 The latest coronavirus research papers

Noah Baker takes a look through some of the key coronavirus papers of the last few weeks.

News: Coronavirus research updates

medRxiv: Full genome viral sequences inform patterns of SARS-CoV-2 spread into and within Israel

Harvard Library: Reductions in commuting mobility predict geographic differences in SARS-CoV-2 prevalence in New York City

Science: DNA vaccine protection against SARS-CoV-2 in rhesus macaques

Never miss an episode: Subscribe to the Nature Podcast on Apple Podcasts, Google Podcasts, Spotify or your favourite podcast app. Head here for the Nature Podcast RSS feed.

Products You May Like

Articles You May Like

REAL TIME – Corona Virus Statistical Data (Worldwide)
Able to power 50,000 homes, the ‘world’s largest floating wind farm’ takes another step forward
NASA Astronauts Aboard ISS To Use Augmented Reality Technology To Repair Tools
Bigeye, providing data quality automation, closes second round this year with $45M
The maddening lack of corporate climate advocacy
Court filing outlines Blue Origin’s case against NASA SpaceX lunar lander award

Leave a Reply

Your email address will not be published. Required fields are marked *